论文部分内容阅读
我国生物技术类药物的研究和开发起步较晚,直到20世纪70年代初才开始将核酸重组技术应用到医学上,但在国家产业政策的支持下,这一领域发展迅速,逐步缩短了与先进国家的差距。目前,国内市场上国产生物药品主要是基因乙肝疫苗、干扰素、白细胞介素-2、GCSF(粒细胞集落刺激因子)、重组链激酶、重组表皮生长因子等15种基因工程药物。T-PA(组织溶纤原激活剂)、白介素-3、重组人工胰岛素、尿激酶等十几种多肽药品
The research and development of biotech drugs in our country started relatively late, and it was not until the early 1970s that the technology of nucleic acid recombination was applied to medicine. However, with the support of the national industrial policy, this field has been developing rapidly and gradually shortened with advanced The gap between countries. At present, domestic bio-pharmaceuticals on the domestic market are mainly gene hepatitis B vaccine, interferon, interleukin-2, GCSF (granulocyte colony stimulating factor), recombinant streptokinase, recombinant epidermal growth factor and other 15 kinds of genetic engineering drugs. T-PA (tissue fibrinogen activator), interleukin-3, recombinant human insulin, urokinase more than a dozen peptide drugs